PrognomiQ Inc. secured $34 million in a series D funding round to advance development of an early detection test for lung cancer based on its multi-omics platform. The blood-based test could provide an alternative to the underutilized low-dose CT scans currently recommended for individuals at high-risk of lung cancer.
Read the full article on BioWorld™ here
